Combining an antiplatelet with oral anticoagulants in stroke patients with AF and cardiovascular disease slightly lowers ...

Researchers have found in a new study that in patients with nonvalvular atrial fibrillation (AF) and atherosclerosis, the addition of antiplatelet therapy to anticoagulants did not reduce ...

Researchers have found in a new study that among patients undergoing valve-in-valve transcatheter aortic procedures, ...

The Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis (ATIS-NVAF) trial included 316 patients from 41 centers in Japan. Mean age was 77.2 ...

For more than 40 years as a researcher and clinician, Joseph Broderick has actively contributed to improvements in stroke ...

In this Review, Zhao and colleagues summarize the major challenges in the implementation of preventative strategies for cardiovascular disease in China and discuss the potential value of digital ...

For more than 40 years as a researcher and clinician, Joseph Broderick has actively contributed to improvements in stroke care, occupying a front row ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that ...

The cardiovascular drugs market was valued at US$ 174.6 billion in 2024 and is projected to reach US$ 247.8 billion by 2033, ...

I read your recent column where you said that ivermectin has not been proven to be an effective treatment for cancer. I feel ...

Although nearly half of patients develop new-onset AF, by 30 days after surgery the burden of the arrythmia is nearly gone, a ...

I am a healthy 69-year-old female. I walk every day and belong to an exercise group that I attend twice a week. I’m writing ...